---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-048293"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T10:13:07.744591+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Senti Biosciences releases initial Phase 1 clinical data for SENTI-202; no specific results disclosed in filing

## Summary
- Initial clinical data from Phase 1 trial of SENTI-202 made available in slide presentation deck.
- Data reported under Item 8.01; no specific numeric results or interim analyses provided in the 8-K body.
- Company cautions forward-looking statements; risks include clinical trial uncertainties.
- Stock ticker SNTI; filing date December 3, 2024.

## SEC filing metadata
- accession: 0001140361-24-048293
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000114036124048293/0001140361-24-048293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000114036124048293/ef20039439_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-048293
- JSON: https://secwatch.observer/filing/0001140361-24-048293.json
- Plain text: https://secwatch.observer/filing/0001140361-24-048293.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.